bimatoprost · Abbvie · NDA 021275, 022184
Lumigan
Earliest generic entry, as listed
13 Jun 2027
Blocked by patent: US 7851504.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7851504 | substance, product | 13 Jun 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 022184-00122 Sep 2025
- 24 Oct 2026Enters 12-month window basis: patent · 022184-00113 Jun 2027
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021275 · 001 · RLD · discontinued | solution/drops, ophthalmic | 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 022184 · 001 · RLD | solution/drops, ophthalmic | 0.01% | 13 Jun 2027 |